ArticleBiomolecules2020
A Combined Proteomics, Metabolomics and In Vivo Analysis Approach for the Characterization of Probiotics in Large-Scale Production.
Article in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- In Vitro and In Vivo Antioxidant and Immune Stimulation Activity of Wheat Product Extracts.Nutrients · 2025Article
- A comprehensive approach, based on the use ofCurrent research in food science · 2025Article
- The Role of Proteomics in Identification of Key Proteins of Bacterial Cells with Focus on Probiotic Bacteria.International journal of molecular sciences · 2024Review
- Heat-killed probiotic Levilactobacillus brevis MKAK9 and its exopolysaccharide promote longevity by modulating aging hallmarks and enhancing immune responses in Caenorhabditis elegans.Immunity & ageing : I & A · 2024Article
- Exploring Therapeutic Advances: A Comprehensive Review of Intestinal Microbiota Modulators.Antibiotics (Basel, Switzerland) · 2024Review
- 'Multi-omics' data integration: applications in probiotics studies.NPJ science of food · 2023Review
- Probiotic-educated Tregs are more potent than naïve Tregs for immune tolerance in stressed new-born mice.Beneficial microbes · 2023Article
- Antibiofilm activity and NMR-based metabolomic characterization of cell-free supernatant ofFrontiers in microbiology · 2023Article
- 2-hydroxyisobutyric acid (2-HIBA) modulates ageing and fat deposition inFrontiers in molecular biosciences · 2022Article
- Challenges in the production and use of probiotics as therapeuticals in cancer treatment or prevention.Journal of industrial microbiology & biotechnology · 2021Review
- Article
- Decrease in Salivary Serotonin in Response to Probiotic Supplementation WithFrontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The manufacturing processes of commercial probiotic strains may be affected in different ways in the attempt to optimize yield, costs, functionality, or stability, influencing gene expression, protein patterns, or metabolic output. Aim of this work is to compare different samples of a high concentration (450 billion bacteria) multispecies (8 strains) formulation produced at two different manufacturing sites, United States of America (US) and Italy (IT), by applying a combination of functional proteomics, metabolomics, and in vivo analyses. Several protein-profile differences were detected between IT- and US-made products, with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.